Banca de DEFESA: SUELLEN MARIA ALBUQUERQUE DA SILVA

Uma banca de DEFESA de DOUTORADO foi cadastrada pelo programa.
STUDENT : SUELLEN MARIA ALBUQUERQUE DA SILVA
DATE: 28/08/2023
TIME: 08:30
LOCAL: ICBS
TITLE:

Evaluation of Leishmanicidal and Antitumor Activity of new Synthetic Anthraquinonic Derivatives.

KEY WORDS:

FALTOU INFORMAR. 

PAGES: 98
BIG AREA: Multidisciplinar
AREA: Biotecnologia
SUMMARY:

Leishmaniasis are diseases caused by protozoa of the genus Leishmania transmitted through infected sandfly vectors. They are endemic in 98 countries and the population at risk of infection is estimated at 350 million. Glioma is the sixth leading cause of cancer-related death worldwide (75% of malignant brain tumors), its most aggressive form is Glioblastoma, with a worldwide incidence of 3.21/100,000 individuals. The treatment adopted in both cases presents a series of adverse events, contraindications and significant toxicity, which can lead the patient to death. The quinone class can develop activities in more than one segment, due to its structure acting as a multi-target therapeutic, a promising group for trials in both therapies. This study proposes to investigate the leishmanicidal and antitumor activity of new synthetic anthraquinone derivatives (DSAQs). For this, nine DSAQs were developed and provided by the Organic Synthesis Laboratory – UFMG and by the Electrochemistry Laboratory LEQUI/UFAL.The in vitro toxicity assay was carried out by the MTT method, on macrophages of the J774.A1 lineage, to evaluate the DSAQs. Leishmanicidal activity was evaluated by in vitro parasite viability assay on extracellular promastigotes of Leishmania amazonensis and Leishmania chagasi. The evaluation of antitumor activity was performed through cell viability assays on Glioblastomas of the GBM02 lineage, using the MTT method. The cytotoxic effect assay on peripheral blood mononuclear cells (PBMC) was performed. Subsequently, the most promising DSAQs were submitted to the following assays: morphological analysis and cell migration. All assays were performed at the Laboratory of Pharmacology and Immunity (LaFI/ICBS/UFAL). In the MTT assay, DSAQs did not reduce 50% of the cell population. Regarding the promastigote assay, ENSJ841, 848, 849 and 854 showed a statistical reduction in parasite viability for Leishmania chagasi, with IC50 between 2.83 ± 0.29 and 71.33 ± 4.04 µM, and ENSJ849, 851 and 854, for Leishmania amazonensis species, with IC50 between 21.33 ± 4.04 and 72.00 ± 7.00 µM. In GBM02 cell viability, ENSJ650, 845, 848 and 854 showed tumor reduction after 72 hours of treatment. DSAQs were not cytotoxic to PBMC. After these assays, only the DSAQs that showed reduction of GBM02 cells, proceeded to the morphology assays, and showed signs of cell death with the presence of cells with rounded cytoplasm, cellular debris, cytoplasmic vacuoles with leakage of contents by membrane rupture. These selected DSAQs, in the cell migration assay, were able to inhibit it, and the percentage of migrated cells ranged from 16 to 51.85%. In view of the results, it is possible to affirm that the DSAQs induce a leishmanicidal and antitumor action, corroborating with the multitherapeutic action of quinone derivatives and in the research of new drugs in both areas.

COMMITTEE MEMBERS:
Presidente - 1358530 - MAGNA SUZANA ALEXANDRE MOREIRA
Interno(a) - 1369387 - JOAO XAVIER DE ARAUJO JUNIOR
Interno(a) - 2272670 - ALINE CAVALCANTI DE QUEIROZ
Externo(a) ao Programa - 1653558 - LUCIANO APARECIDO MEIRELES GRILLO - UFALExterno(a) ao Programa - 1544773 - TIAGO GOMES DE ANDRADE - UFALExterno(a) ao Programa - 1527220 - CAMILA BRAGA DORNELAS - UFALExterno(a) ao Programa - ***.836.334-** - JOHNNATAN DUARTE DE FREITAS - IFAL
Externo(a) à Instituição - MAX DENISSON MAURÍCIO VIANA - UFBA